REGENXBIO Investors Face April 14 Deadline to Seek Lead Role in Securities Suit

Plaintiffs tie losses to FDA trial holds disclosed Jan. 28 after a reported tumor in a participant.

Overview

A federal securities class action has been filed against REGENXBIO over statements related to its RGX-111 gene therapy program.
The putative class covers investors who purchased REGENXBIO securities from February 9, 2022 through January 27, 2026.
The complaint alleges the company and executives made false or misleading statements and concealed material safety and efficacy risks for RGX-111.
On January 28, 2026, REGENXBIO disclosed FDA clinical holds on RGX-111 and RGX-121 following preliminary analysis of a single intraventricular CNS tumor in a Phase I/II participant, and the stock fell 17.9% to $11.01 that day.
Rosen Law Firm and Faruqi & Faruqi are urging investors to contact them and to move for lead plaintiff status by April 14, 2026, noting that no class has yet been certified and participation does not depend on serving as lead plaintiff.